- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.02. | AdvanCell, Lilly partner on new targeted alpha therapies for cancer treatment | ||
| 10.02. | Norgine launches sodium thiosulfate injection in Germany | ||
| 07.02. | Essential and Clinigen expand JAPAC partnership to drive patient access | ||
| 06.02. | DEBRA Research and LEO Pharma partner for skin disease therapies | ||
| 05.02. | FDA clears Auron's AUTX-703 IND to treat haematological malignancies | ||
| 04.02. | BioNTech concludes acquisition of biotechnology company Biotheus | ||
| 03.02. | EMA's CHMP recommends approval of Bristol Myers Squibb's HCC treatment combo | ||
| 31.01. | Rad AI raises $60m to accelerate generative AI technology development | ||
| 30.01. | Scholar Rock submits application of SMA therapy to FDA | ||
| 29.01. | Atalanta Therapeutics secures $97m in Series B round to advance RNAi therapies | ||
| 28.01. | Manas AI launches to focus on cancer medicine discovery | ||
| 27.01. | EMA validates X4's mavorixafor application for WHIM syndrome treatment | ||
| 24.01. | FDA approves Amneal Pharmaceuticals' Alzheimer's and oncology treatments | ||
| 23.01. | Kamada to supply immune globulin products in Latin America | ||
| 22.01. | FDA grants fast track status to Nacuity's NPI-001 for retinitis pigmentosa | ||
| 21.01. | Health Canada authorises Roche's Vabysmo for certain eye conditions | ||
| 20.01. | Fermion and Simcere to partner on development of pain treatment drug | ||
| 17.01. | Micron Biomedical secures funds for needle-free vaccine development | ||
| 16.01. | FDA clears Axcynsis' AT03-65 IND for CLDN6-positive solid tumours | ||
| 15.01. | Cycle expands MS treatment portfolio with Banner Life Sciences acquisition | ||
| 13.01. | JW Therapeutics' Carteyva receives breakthrough therapy status for r/r LBCL | ||
| 10.01. | RheumaGen secures $15m in Series A funding to advance RA therapies | ||
| 09.01. | Parvus and Resilience expand partnership to develop IBD drug candidate | ||
| 08.01. | FDA grants priority review to Dizal's sunvozertinib NDA for NSCLC treatment | ||
| 07.01. | Star Therapeutics' von Willebrand disease therapy gains FDA fast track status |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
